Nuo Therapeutics, Inc. (AURX) financial statements (2021 and earlier)

Company profile

Business Address 209 PERRY PARKWAY,
GAITHERSBURG,, MD 20877
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments11311633
Cash and cash equivalents11311633
Restricted cash and investments  000  
Receivables0001363
Inventory, net of allowances, customer advances and progress billings0000111
Inventory0000111
Prepaid expense   011
Deferred costs    100
Prepaid expense and other current assets1
Deferred tax assets    (14)(3)(3)
Other current assets     0
Other undisclosed current assets00011422
Total current assets:113322106
Noncurrent Assets
Property, plant and equipment00011(1)(1)
Intangible assets, net (including goodwill)  103303535
Goodwill  2 111
Intangible assets, net (excluding goodwill)  83293434
Deferred costs    400
Other noncurrent assets0000  
Other undisclosed noncurrent assets     24
Total noncurrent assets:00114343638
TOTAL ASSETS:11147564644
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1117983
Accounts payable0001231
Accrued liabilities01126  
Employee-related liabilities    111
Interest and dividends payable0  3   
Other undisclosed accounts payable and accrued liabilities     41
Debt0  35 2 
Derivative instruments and hedges, liabilities0      
Deferred revenue and credits  101 
Customer advances and deposits   3
Other undisclosed current liabilities    (4)  
Total current liabilities:111428113
Noncurrent Liabilities
Long-term debt and lease obligation    043
Long-term debt, excluding current maturities    043
Liabilities, other than long-term debt 0013151
Deferred revenue and credits  111 
Other liabilities 0001  
Derivative instruments and hedges, liabilities    3031
Other undisclosed noncurrent liabilities     10
Total noncurrent liabilities: 0013294
Total liabilities:1124340196
Temporary equity, carrying amount   11  
Stockholders' equity
Stockholders' equity attributable to parent, including:(0)012(37)152638
Preferred stock000    
Common stock0000000
Additional paid in capital222118126125117108
Accumulated deficit(22)(21)(6)(163)(110)(91)(71)
Other undisclosed stockholders' equity attributable to parent   0000
Other undisclosed stockholders' equity     1 
Total stockholders' equity:(0)012(37)152738
TOTAL LIABILITIES AND EQUITY:11147564644

Income statement (P&L) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues11 1281211
Revenue, net1 128107
Cost of revenue(0)(1) (8)(7)(8)(4)
Cost of goods and services sold(0)(1) (8)(7)(9)(4)
Gross profit:1(0) 4137
Operating expenses(3)(15) (45)(24)(21)(20)
Operating loss:(2)(16) (41)(23)(18)(13)
Nonoperating income (expense)(0)1 (12)5(2)(7)
Investment income, nonoperating   308(0)0
Other nonoperating income (expense)01 (0)(0)0(0)
Interest and debt expense(0)(0) (39)   
Loss from continuing operations before equity method investments, income taxes:(2)(15) (92)(19)(20)(20)
Other undisclosed income from continuing operations before income taxes00 39   
Loss from continuing operations before income taxes:(2)(15) (53)(19)(20)(20)
Income tax expense (benefit)(0)14 0(0)(0)(0)
Net loss:(2)(1) (53)(19)(20)(20)
Other undisclosed net income (loss) attributable to parent0(14)     
Net loss attributable to parent:(2)(15) (53)(19)(20)(20)
Preferred stock dividends and other adjustments      (2)
Other undisclosed net income available to common stockholders, basic      1
Net loss available to common stockholders, diluted:(2)(15) (53)(19)(20)(20)

Comprehensive Income ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(2)(1) (53)(19)(20)(20)
Comprehensive loss, net of tax, attributable to parent:(2)(1) (53)(19)(20)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: